Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma

Fineline Cube May 21, 2026
Policy / Regulatory

Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program

Fineline Cube Feb 6, 2026

The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening...

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Fineline Cube Feb 5, 2026

Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Fineline Cube Feb 5, 2026

Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026

Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Fineline Cube Feb 5, 2026

GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year...

Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026

Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...

Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the initiation of a Phase I clinical...

Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026

Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...

Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026

Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) announced that the National Medical Products Administration (NMPA)...

Company

Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion

Fineline Cube Feb 5, 2026

Innovent Biologics, Inc. (HKG: 1801) reported strong financial results for Q4 and full‑year 2025, with total...

Company Drug

Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study

Fineline Cube Feb 5, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...

Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026

Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...

Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026

China’s National Health Commission (NHC) has approved the “Standardized Pilot Program for Online Initial Consultations...

Company Drug

AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter

Fineline Cube Feb 5, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....

Company

AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025

Fineline Cube Feb 5, 2026

AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025...

Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026

Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...

Company Deals

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Fineline Cube Feb 5, 2026

Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Fineline Cube Feb 4, 2026

Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Fineline Cube Feb 4, 2026

Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026

Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...

Posts pagination

1 … 49 50 51 … 669

Recent updates

  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
  • Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Company Medical Device

Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.